免疫炎症通过激活SOCS6/STAT6通路调控前列腺细胞增殖

doi:10.20223/j.cnki.1000-8535.2025.08.006

广州医药 ›› 2025, Vol. 56 ›› Issue (8): 1055-1060.DOI: 10.20223/j.cnki.1000-8535.2025.08.006

免疫炎症通过激活SOCS6/STAT6通路调控前列腺细胞增殖

陈锦延, 李思宁

广东医科大学附属医院泌尿外科（广东湛江 524000）

收稿日期:2024-07-16 出版日期:2025-08-20 发布日期:2025-09-17
通讯作者: 李思宁,E-mail：qiupingshiyue32@126.com
基金资助:
广东医科大学青年培育基金（GDMUQ2021017）

SOCS6/STAT6 pathway regulates inflammatory proliferation of prostatic cells

CHEN Jinyan, LI Sining

Department of Urology,Affiliated Hospital of Guangdong Medical University Zhanjiang,Zhanjiang 524000,China

Received:2024-07-16 Online:2025-08-20 Published:2025-09-17

摘要/Abstract

摘要： 目的研究SOCS6/STAT6通路在前列腺细胞炎性增殖作用中的调控作用。方法使用人前列腺细胞株RWPE-1建立炎症模型,将细胞分为对照（CON）组和炎症刺激（INF）组,后者通过添加脂多糖（LPS）模拟炎症环境。采用ELISA检测白细胞介素-1β（IL-1β）-1β、白细胞介素-6（IL-6）和白细胞介素-8（IL-8）表达水平,蛋白免疫印迹法检测细胞因子信号抑制物-6（SOCS6）、信号转导和转录激活因子-6（STAT6）及磷酸化STAT6蛋白的表达水平。结果经过LPS处理后,RWPE-1细胞中的SOCS6蛋白表达水平显著下降（P<0.01）,而磷酸化STAT6表达水平上升（P<0.01）。结论 SOCS6/STAT6通路可能通过调节炎症环境下STAT6的磷酸化水平,参与调节前列腺细胞的炎性增殖作用。

关键词: SOCS6, STAT6, 前列腺增生, 炎症, 细胞增殖

Abstract: Objective To explore the regulatory role of SOCS6/STAT6 pathway in the inflammatory proliferation of prostate cells．Methods The human prostate cell line RWPE-1 was used to establish an inflammation model．Cells were divided into a control（CON）group and an inflammation-stimulated（INF）group,with the latter subjected to lipopolysaccharide（LPS）treatment to simulate an inflammatory environment．The expression levels of interleukin（IL）-1β、IL-6 and IL-8 were detected by ELISA,and the expression levels of suppressor of cytokine signaling 6（SOCS6）,signal transducer and activator oftranscription-6,（STAT6）,and phosphorylated STAT6 proteins were detected by Western blot．Results The results showed that after LPS treatment,the expression of SOCS6 protein in RWPE-1 cells significantly decreased,while the expression of phosphorylated STAT6 increased．Conclusions The SOCS6/STAT6 pathway may be involved in regulating the inflammatory proliferation of prostate cells by modulating the phosphorylation level of STAT6 under inflammatory conditions．

Key words: SOCS6, STAT6, benign prostatic hyperplasia, inflammation, cell proliferation

陈锦延, 李思宁. 免疫炎症通过激活SOCS6/STAT6通路调控前列腺细胞增殖[J]. 广州医药, 2025, 56(8): 1055-1060.

CHEN Jinyan, LI Sining. SOCS6/STAT6 pathway regulates inflammatory proliferation of prostatic cells[J]. Guangzhou Medical Journal, 2025, 56(8): 1055-1060.

参考文献

[1] GBD Benign Prostatic Hyperplasia Collaborators.The global,regional,and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019:A systematic analysis for the Global Burden of Disease Study 2019[J].Lancet Healthy Longev,2022,3(11):e754-e776.
[2] DONNELL R F.Benign prostate hyperplasia:A review of the year's progress from bench to clinic[J].Curr Opin Urol,2011,21(1):22-26.
[3] ALGABA F.Pathophysiology of benign prostatic hyperplasia[J].Eur Urol,1994,25(Suppl 1):3-5.
[4] GANDAGLIA G,BRIGANTI A,GONTERO P,et al.The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia(BPH)[J].BJU Int,2013,112(4):432-441.
[5] de NUNZIO C,KRAMER G,MARBERGER M,et,al.The controversial relationship between benign prostatic hyperplasia and prostate cancer:The role of inflammation[J].Eur Urol,2011,60(1):106-117.
[6] WANG L,LI Y,HONG F,et al.Circ_0062491 alleviates LPS-induced apoptosis and inflammation in periodontitis by regulating miR-498/SOCS6 axis[J].Innate Immun,2022,28(5):174-184.
[7] SUN L,KE M,YIN M,et al.Extracellular vesicle-encapsulated microRNA-296-3p from cancer-associated fibroblasts promotes ovarian cancer development through regulation of the PTEN/AKT and SOCS6/STAT3 pathways[J].Cancer Sci,2024,115(1):155-169.
[8] YANG Z,HUANG S,ZHAO L.Suppressor of cytokine signaling 6 in cancer development and therapy:Deciphering its emerging and suppressive roles[J].Cytokine Growth Factor Rev,2022(64):21-32.
[9] LIN H Y,LAI R H,LIN S T,et al.Suppressor of cytokine signaling 6(SOCS6)promotes mitochondrial fission via regulating DRP1 translocation[J].Cell Death Differ,2013,20(1):139-153.
[10] LI J,DENG H,HU M,et al.Inhibition of non-small cell lung cancer(NSCLC)growth by a novel small molecular inhibitor of EGFR[J].Oncotarget,2015,6(9):6749-6761.
[11] YUAN D,WANG W,SU J,et al.SOCS6 functions as a tumor suppressor by inducing apoptosis and inhibiting angiogenesis in human prostate cancer[J].Curr Cancer Drug Targets,2018,18(9):894-904.
[12] OUYANG J,AN T,WANG Y,et al.Down-regulation of SOCS6:An unfavorable prognostic factor for gastrointestinal stromal tumor proven by survival analysis[J].Diagn Pathol,2021,16(1):113.
[13] STRAND D W,COSTA D N,FRANCIS F,et al.Targeting phenotypic heterogeneity in benign prostatic hyperplasia[J].Differentiation,2017(96):49-61.
[14] STEWART K L,LEPHART E D.Overview of BPH:Symptom relief with dietary polyphenols,vitamins and phytochemicals by nutraceutical supplements with implications to the prostate microbiome[J].Int J Mol Sci,2023,24(6):5486.
[15] SOBAH M L,LIONGUE C,WARD A C.SOCS proteins in immunity,inflammatory diseases,and immune-related cancer[J].Front Med,2021(8):727987.
[16] LI C,ZHANG W,FANG T,et al.Identification of the prognostic value among suppressor of cytokine signaling family members in kidney renal clear cell carcinoma[J].Front Mol Biosci,2021(8):585000.
[17] WONG G L,MANORE S G,DOHENY D L,et al.STAT family of transcription factors in breast cancer:Pathogenesis and therapeutic opportunities and challenges[J].Semin Cancer Biol,2022,86(Pt 3):84-106.
[18] HUANG S,LIU K,CHENG A,et al.SOCS proteins participate in the regulation of innate immune response caused by viruses[J].Front Immunol,2020(11):558341.

免疫炎症通过激活SOCS6/STAT6通路调控前列腺细胞增殖

SOCS6/STAT6 pathway regulates inflammatory proliferation of prostatic cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李复印, 杨雪艳, 刘莉, 张海, 田威. 支气管镜灌洗对儿童重症肺部感染合并肺实变的应用效果及对CT特征、肺功能影响[J]. 广州医药, 2025, 56(7): 951-956.
[2]	赵柳淇, 戴世学, 沙卫红. 人工智能在炎症性肠病图像诊断的应用进展[J]. 广州医药, 2025, 56(5): 571-580.
[3]	秦月坛, 秦月鹏. 双极半髋关节置换术与全髋关节置换术对股骨颈骨折患者炎症因子水平及髋关节活动度的影响[J]. 广州医药, 2025, 56(5): 638-643.
[4]	赵雨晨, 黄琛. 炎症性肠病相关易感基因及其作用机制的研究进展[J]. 广州医药, 2025, 56(3): 300-309.
[5]	朱怡怡, 杨婵, 王振兴. 全身免疫炎症指数与心血管疾病相关研究进展[J]. 广州医药, 2024, 55(9): 985-990.
[6]	谢娟, 李汝峰, 陈婧, 李珉珉. 减重手术对炎症因子影响的研究进展[J]. 广州医药, 2024, 55(5): 463-471.
[7]	伍洪森, 湛炜璋, 蔡正凯. 输尿管软镜下钬激光碎石术治疗直径≤3 cm肾结石的疗效观察[J]. 广州医药, 2024, 55(4): 401-405.
[8]	程海琪, 周薇, 李萍, 杜丹阳, 刘秋丽, 彭倩菲. 炎症性肠病患者运动锻炼的证据总结[J]. 广州医药, 2024, 55(12): 1397-1406.
[9]	秦永生, 苏俊, 牟欣奕, 石若湖, 陈国兵, 高利娟. 血清中炎症因子与炎性衰老的相关性研究[J]. 广州医药, 2024, 55(12): 1407-1413.
[10]	李建洪, 徐婧, 徐豪明, 黄琛, 聂玉强, 周有连. 肠道菌群-PPARs轴在炎症性肠病中的作用[J]. 广州医药, 2024, 55(11): 1246-1254.
[11]	张焕涛, 钟丽芳, 徐艳萍, 淡明江. 良性前列腺增生患者手术接受意愿调查及影响因素研究[J]. 广州医药, 2024, 55(11): 1282-1289.
[12]	刘丽, 张明, 任建兵, 米奇珍, 闫有鹏. 复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期患者的疗效及安全性研究[J]. 广州医药, 2024, 55(10): 1177-1182.
[13]	赵茜颖, 李俊. 宣清导浊汤加减方联合血液透析治疗对老年慢性肾衰竭患者微炎症状态和毒素清除率的影响[J]. 广州医药, 2024, 55(1): 25-29.
[14]	王颖. 甲泼尼龙琥珀酸钠对重症支原体肺炎患儿症状消失时间及炎症反应的影响[J]. 广州医药, 2024, 55(1): 54-58.
[15]	肖丽姣, 温小军. SII、NLR和PLR 水平对急性缺血性卒中伴发卵圆孔未闭的诊断价值[J]. 广州医药, 2023, 54(9): 28-33.